{"id":"docetaxel-high-dose-vitamin-d2","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"50–70","effect":"Anemia"},{"rate":"25–50","effect":"Thrombocytopenia"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"5–10","effect":"Hypersensitivity reactions"},{"rate":"30–50","effect":"Nausea and vomiting"},{"rate":"40–60","effect":"Fatigue"},{"rate":"null","effect":"Hypercalcemia (from high-dose vitamin D2)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. High-dose vitamin D2 supplementation may modulate immune function and enhance the anti-tumor effects of chemotherapy through vitamin D receptor signaling and potential immunomodulatory mechanisms.","oneSentence":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while high-dose vitamin D2 may enhance immune response and potentially sensitize cancer cells to chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:39.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced solid tumors (under investigation with vitamin D2 co-treatment)"}]},"trialDetails":[{"nctId":"NCT00944424","phase":"PHASE3","title":"Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel + High dose Vitamin D2","genericName":"Docetaxel + High dose Vitamin D2","companyName":"King Faisal Specialist Hospital & Research Center","companyId":"king-faisal-specialist-hospital-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while high-dose vitamin D2 may enhance immune response and potentially sensitize cancer cells to chemotherapy. Used for Metastatic or locally advanced solid tumors (under investigation with vitamin D2 co-treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}